Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Expected to Earn FY2022 Earnings of ($6.65) Per Share

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for shares of Arcturus Therapeutics in a research report issued on Monday, May 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the biotechnology company will earn ($6.65) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.

Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.44) by ($0.50). Arcturus Therapeutics had a negative return on equity of 61.88% and a negative net margin of 1,647.99%. During the same quarter last year, the company posted ($2.15) earnings per share.

A number of other equities research analysts have also recently commented on ARCT. StockNews.com initiated coverage on shares of Arcturus Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Guggenheim dropped their price objective on shares of Arcturus Therapeutics from $83.00 to $36.00 in a research note on Wednesday. Raymond James raised shares of Arcturus Therapeutics from an “underperform” rating to a “market perform” rating in a research note on Monday, January 31st. Citigroup lowered Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $86.00 to $29.00 in a research report on Thursday, April 21st. Finally, Barclays decreased their target price on Arcturus Therapeutics from $21.00 to $17.00 in a research report on Tuesday. Five equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $40.22.

Shares of NASDAQ:ARCT opened at $13.04 on Thursday. Arcturus Therapeutics has a twelve month low of $12.87 and a twelve month high of $65.00. The company’s 50 day moving average is $23.38 and its 200 day moving average is $30.02. The company has a market cap of $344.50 million, a PE ratio of -1.68 and a beta of 2.79.

Large investors have recently modified their holdings of the stock. BlackRock Inc. grew its position in Arcturus Therapeutics by 1.0% in the 3rd quarter. BlackRock Inc. now owns 1,720,708 shares of the biotechnology company’s stock valued at $82,216,000 after acquiring an additional 17,199 shares in the last quarter. Tudor Investment Corp Et Al purchased a new stake in Arcturus Therapeutics during the third quarter worth approximately $273,000. Point72 Hong Kong Ltd purchased a new stake in Arcturus Therapeutics during the third quarter worth approximately $116,000. DekaBank Deutsche Girozentrale lifted its stake in Arcturus Therapeutics by 2.6% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 23,700 shares of the biotechnology company’s stock worth $920,000 after purchasing an additional 600 shares during the last quarter. Finally, ACT Capital Management LLC lifted its stake in Arcturus Therapeutics by 5.3% during the fourth quarter. ACT Capital Management LLC now owns 479,400 shares of the biotechnology company’s stock worth $17,743,000 after purchasing an additional 24,100 shares during the last quarter. 80.10% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile (Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

See Also